Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Sanford Project: T-Rex Study
NCT02691247Phase 2Completed
- Sponsor
- Lisata Therapeutics
- Start
- Feb 2016
- Primary completion
- Mar 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CLBS03 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Lisata Therapeutics. Primary endpoint: Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at 52 weeks. Started Feb 2016; status: completed.
02
Drugs
CLBS03
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02691247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691247.